About Novartis AG (NYSE:NVS)
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NYSE:NVS
- CUSIP: N/A
- Web: www.novartis.com
- Market Cap: $204.24547 billion
- Outstanding Shares: 2,616,845,000
- 50 Day Moving Avg: $85.46
- 200 Day Moving Avg: $82.10
- 52 Week Range: $66.93 - $86.90
Sales & Book Value:
- Trailing P/E Ratio: 31.41
- Foreward P/E Ratio: 16.90
- P/E Growth: 2.95
- Annual Revenue: $49.18 billion
- Price / Sales: 4.58
- Book Value: $29.84 per share
- Price / Book: 2.88
- Annual Dividend: $2.30
- Dividend Yield: 2.7%
- EBITDA: $14.46 billion
- Net Margins: 13.52%
- Return on Equity: 15.51%
- Return on Assets: 8.41%
- Debt-to-Equity Ratio: 0.33%
- Current Ratio: 1.01%
- Quick Ratio: 0.75%
- Average Volume: 1.57 million shs.
- Beta: 0.73
- Short Ratio: 1.69
Frequently Asked Questions for Novartis AG (NYSE:NVS)
What is Novartis AG's stock symbol?
Novartis AG trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."
How often does Novartis AG pay dividends? What is the dividend yield for Novartis AG?
Novartis AG announced an annual dividend on Friday, January 27th. Shareholders of record on Friday, March 3rd will be given a dividend of $2.327 per share on Friday, March 3rd. The ex-dividend date is Wednesday, March 1st. View Novartis AG's Dividend History.
How will Novartis AG's stock buyback program work?
Novartis AG declared that its board has approved a share buyback program on Saturday, April 8th 2017, which permits the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 2.9% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's leadership believes its stock is undervalued.
How were Novartis AG's earnings last quarter?
Novartis AG (NYSE:NVS) released its quarterly earnings results on Tuesday, July, 19th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.18 by $0.05. The company had revenue of $12.47 billion for the quarter, compared to analyst estimates of $12.33 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. During the same quarter in the prior year, the firm posted $1.25 earnings per share. View Novartis AG's Earnings History.
When will Novartis AG make its next earnings announcement?
Where is Novartis AG's stock going? Where will Novartis AG's stock price be in 2017?
13 brokerages have issued 1-year price targets for Novartis AG's shares. Their forecasts range from $74.37 to $90.00. On average, they expect Novartis AG's share price to reach $82.92 in the next twelve months. View Analyst Ratings for Novartis AG.
Are investors shorting Novartis AG?
Novartis AG saw a drop in short interest in the month of September. As of September 15th, there was short interest totalling 1,327,917 shares, a drop of 33.5% from the August 31st total of 1,996,918 shares. Based on an average daily trading volume, of 1,788,278 shares, the days-to-cover ratio is presently 0.7 days.
Who are some of Novartis AG's key competitors?
Some companies that are related to Novartis AG include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Company (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), Celgene Corporation (CELG), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA) and Dr. Reddy's Laboratories Ltd (RDY).
Who are Novartis AG's key executives?
Novartis AG's management team includes the folowing people:
- Joseph S. Jimenez, Chief Executive Officer, Member of the Executive Committee
- Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
- Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee
- James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
- Richard D. Francis, Chief Executive Officer of Sandoz Division, Member of the Executive Committee
- Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
- Bruno Strigini, Chief Executive Officer of Novartis Oncology, Member of the Executive Committee
- Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee
- Steven Baert, Head of Human Resources, Member of the Executive Committee
- Vasant Narasimhan M.D., Chief Executive Officer, Member of the Executive Committee
Who owns Novartis AG stock?
Novartis AG's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Park National Corp OH (0.01%), Osborn Williams & Donohoe LLC (0.00%), Beacon Financial Group (0.00%), Eqis Capital Management Inc. (0.00%) and Private Asset Management Inc. (0.00%). Company insiders that own Novartis AG stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis AG.
Who sold Novartis AG stock? Who is selling Novartis AG stock?
Who bought Novartis AG stock? Who is buying Novartis AG stock?
Novartis AG's stock was purchased by a variety of institutional investors in the last quarter, including Park National Corp OH, Beacon Financial Group and Eqis Capital Management Inc.. Company insiders that have bought Novartis AG stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis AG.
How do I buy Novartis AG stock?
Shares of Novartis AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novartis AG's stock price today?
MarketBeat Community Rating for Novartis AG (NYSE NVS)MarketBeat's community ratings are surveys of what our community members think about Novartis AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Novartis AG stock can currently be purchased for approximately $86.04.
Consensus Ratings for Novartis AG (NYSE:NVS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Sell Ratings, 7 Hold Ratings, 4 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.15)|
|Consensus Price Target: ||$82.92 (3.62% downside)|Consensus Price Target History for Novartis AG (NYSE:NVS)
Analysts' Ratings History for Novartis AG (NYSE:NVS)
(Data available from 10/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/10/2017||J P Morgan Chase & Co||Reiterated Rating||Neutral||N/A|
|8/9/2017||Cowen and Company||Set Price Target||Hold||$90.00||Medium|
|7/26/2017||Morgan Stanley||Upgrade||Underweight -> Overweight||Low|
|7/5/2017||Credit Suisse Group||Downgrade||Neutral -> Underperform||$82.25||Medium|
|6/22/2017||Leerink Swann||Reiterated Rating||Market Perform||$83.00||Low|
|6/22/2017||Barclays PLC||Upgrade||Underweight -> Equal Weight||Low|
|3/22/2017||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Neutral||Low|
|3/9/2017||Liberum Capital||Initiated Coverage||Buy -> Buy||Low|
|3/7/2017||Societe Generale||Upgrade||Hold -> Buy||$73.82 -> $74.37||N/A|
|3/7/2017||BNP Paribas||Downgrade||Neutral -> Underperform||N/A|
|1/31/2017||Argus||Upgrade||Hold -> Buy||N/A|
|1/17/2017||Berenberg Bank||Downgrade||Buy -> Hold||N/A|
|1/9/2017||Deutsche Bank AG||Reiterated Rating||Neutral||N/A|
|10/16/2016||Jefferies Group LLC||Reiterated Rating||Buy||N/A|
|10/10/2016||Chardan Capital||Lower Price Target||Buy||$95.00 -> $92.00||N/A|
|7/12/2016||Bank of America Corporation||Reiterated Rating||Hold||N/A|
|5/24/2016||Citigroup Inc.||Reiterated Rating||Neutral||N/A|
|10/28/2015||Sanford C. Bernstein||Lower Price Target||Outperform||$102.00||N/A|
|10/28/2015||Main First Bank AG||Downgrade||Underperform||N/A|
Earnings History for Novartis AG (NYSE:NVS)Earnings History by Quarter for Novartis AG (NYSE NVS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/18/2017||Q2 17||$1.16||$1.22||$12.20 billion||$12.24 billion||View||N/A|
|4/25/2017||3/31/2017||$1.10||$1.13||$11.59 billion||$11.54 billion||View||N/A|
|1/25/2017||Q416||$1.12||$1.12||$12.44 billion||$12.32 billion||View||N/A|
|10/25/2016||Q316||$1.19||$1.23||$12.24 billion||$12.13 billion||View||Listen|
|7/19/2016||Q216||$1.18||$1.23||$12.33 billion||$12.47 billion||View||Listen|
|4/21/2016||Q116||$1.18||$1.17||$11.90 billion||$11.60 billion||View||Listen|
|1/27/2016||Q415||$1.18||$1.14||$12.64 billion||$12.52 billion||View||Listen|
|10/27/2015||Q315||$1.31||$1.27||$12.66 billion||$12.30 billion||View||Listen|
|7/21/2015||Q215||$1.20||$1.27||$12.45 billion||$12.70 billion||View||Listen|
|4/23/2015||Q115||$1.12||$1.33||$12.90 million||$11.94 billion||View||N/A|
|1/27/2015||Q314||$1.13||$1.21||$14.68 billion||$14.63 billion||View||N/A|
|7/17/2014||Q214||$1.36||$1.36||$14.83 billion||$14.64 billion||View||N/A|
|4/24/2014||Q1 2014||$1.33||$1.31||$14.25 billion||$14.02 billion||View||N/A|
|1/29/2014||Q413||$1.27||$1.20||$15.16 billion||$15.08 billion||View||N/A|
|10/22/2013||Q313||$1.31||$1.26||$14.28 billion||$14.34 billion||View||N/A|
|7/17/2013||Q213||$1.29||$1.30||$14.39 billion||$14.50 billion||View||N/A|
|4/24/2013||Q113||$1.28||$1.32||$14.02 million||$14.02 billion||View||N/A|
|1/23/2013||Q412||$1.19||$1.27||$14.42 billion||$14.80 billion||View||N/A|
Earnings Estimates for Novartis AG (NYSE:NVS)
2017 EPS Consensus Estimate: $4.75
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Novartis AG (NYSE:NVS)
|Most Recent Dividend:||3/3/2017|
|Dividend Growth:||3.90% (3 Year Average)|
|Payout Ratio:||83.94% (Trailing 12 Months of Earnings) |
48.32% (Based on This Year's Estimates)
45.19% (Based on Next Year's Estimates)
Dividend History by Quarter for Novartis AG (NYSE NVS)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Novartis AG (NYSE:NVS)
Insider Ownership Percentage: 0.01%Insider Trades by Quarter for Novartis AG (NYSE:NVS)
Institutional Ownership Percentage: 10.93%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/5/2017||Bioventures Ltd Novartis||Major Shareholder||Buy||266,667||$15.00||$4,000,005.00|| |
|5/11/2016||Institutes For Biomed Novartis||Major Shareholder||Buy||277,777||$18.00||$4,999,986.00|| |
|2/17/2016||Bioventures Ltd Novartis||Major Shareholder||Buy||375,000||$8.00||$3,000,000.00|| |
|9/22/2014||Bioventures Ltd Novartis||Major Shareholder||Buy||325,000||$15.00||$4,875,000.00|| |
Headline Trends for Novartis AG (NYSE:NVS)
Latest Headlines for Novartis AG (NYSE:NVS)
Novartis AG (NVS) Chart for Thursday, October, 19, 2017